LDS/Medical Tests/Pompe Disease (GAA) Gene Mutation Analysis

Pompe Disease (GAA) Gene Mutation Analysis

Pompe disease, also known as glycogen storage disease type II, is an autosomal recessive metabolic disorder caused by a deficiency of acid alpha-glucosidase (AAG). Deficiency of AAG impairs the ability of cells to break down glycogen into glucose within lysosomes. This leads to glycogen accumulation, primarily in hepatocytes and cardiac and skeletal myocytes, resulting in their dysfunction. Classification of Pompe disease is based on age of onset, organ involvement, severity, and the rate of disease progression.

Two major forms of GSD II are recognized: infantile-onset Pompe disease (IOPD), and late-onset Pompe disease (LOPD). IOPD begins within the first few months after birth and infants with this disorder typically have muscle weakness (myopathy), poor muscle tone (hypotonia), hepatomegaly, and cardiomyopathy. Infants with IOPD who do not receive enzyme replacement therapy (ERT) typically die by 2 years of age from left ventricular dysfunction and respiratory insufficiency. LOPD includes patients with disease onset prior to 12 months of age without cardiomyopathy and any patient with onset after 12 months of age. LOPD is characterized by proximal muscle weakness and respiratory insufficiency, cardiomyopathy is uncommon. Together both forms of Pompe disease affect an estimated 1 in 40,000 to 60,000 people in the United States. The incidence of this disorder varies among different ethnic groups.

Pompe disease is caused by mutations in the GAA gene on chromosome 17 at position q25.3 that encodes acid alpha-glucosidase (also known as acid maltase or lysosomal alpha glucosidase). More than 150 pathogenic variants in GAA have been described. Patients who inherit two pathogenic variants that result in complete absence of AAG tend to have IOPD while those that result in partial deficiency tend to have LOPD.

  • Diagnosis confirmation of Pompe disease
  • Carrier screening in family members of the affected patient
  • Prenatal diagnosis in at-risk pregnancies
Depends on the variants (heterozygous or homozygous), individuals can be carrier or affected with Pompe disease.

Negative for mutation or pathogenic variant in GAA gene

Next-Generation (NGS)/Massively parallel sequencing (MPS), Conventional sequencing.

Whole blood, Skin biopsy.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Acid alpha-glucosidase enzyme analysis, GAA deletion/duplication analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login